LIPOPEPTIDES AND LIPOPEPTIDE SYNTHETASES

• US 20110030103A1
• Filed: 04/16/2008
• Published: 02/03/2011
• Est. Priority Date: 04/16/2007
• Status: Abandoned Application

• Current Assignee: Gabriel Reznik, Kevin A. Jarrell, Prashanth Vishwanath
• Original Assignee: Gabriel Reznik, Kevin A. Jarrell, Prashanth Vishwanath
• Inventors: Reznik, Gabriel, Vishwanath, Prashanth, Jarrell, Kevin A.
• Application Number:
  US12/596,276
• Publication Number:
  US 20110030103A1
• Time in Patent Office: Days
• US Class Current: 800/298
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: C07K 7/06 having 5 to 11 amino acids
• CPC Class Codes: C12N 9/93 Ligases (6)

Abstract

Novel lipopeptides, and engineered polypeptides useful in synthesizing lipopeptides are provided. Also provided are methods of making lipopeptides using engineered polypeptides, and methods of using lipopeptides, e.g., as insecticidal and/or antimicrobial agents.

Claims

1. An engineered lipopeptide synthetase polypeptide which is a deletion mutant of a naturally occurring lipopeptide synthetase polypeptide,

wherein the naturally occurring polypeptide comprises a first and second peptide synthetase domain, wherein each peptide synthetase domain comprises a condensation domain (C domain), an adenylation domain (A domain), and a thiolation domain (T domain),

wherein the engineered polypeptide comprises a deletion of at least a portion of a C domain, a portion of an A domain, or a portion of a T domain, relative to the naturally occurring lipopeptide synthetase polypeptide, and wherein the engineered polypeptide comprises a fatty acid linkage domain.

2. The engineered polypeptide of claim 1, wherein the engineered polypeptide produces a lipopeptide having one less amino acid than a lipopeptide produced by the naturally occurring polypeptide, when expressed under conditions in which the naturally occurring polypeptide produces the naturally occurring lipopeptide.

3. The engineered polypeptide of claim 1, wherein the engineered polypeptide comprises a deletion of at least a C domain and an A domain, relative to the naturally occurring lipopeptide synthetase polypeptide.

4. The engineered polypeptide of claim 3, wherein the engineered polypeptide comprises a deletion of a C domain and A domain of the second peptide synthetase domain.

5. The engineered polypeptide of claim 4, wherein the engineered polypeptide comprises a C domain and A domain of the first peptide synthetase domain, fused to a T domain which is a hybrid T domain comprising a portion of the T domain from the first peptide synthetase domain, and a portion of the T domain from the second peptide synthetase domain.

6. The engineered polypeptide of claim 5, wherein the engineered polypeptide comprises the C and A domains of the first module of SrfA-A, fused to a T domain which comprises a portion of the T domain of the first module of SrfA-A and a portion of the T domain of the second module of SrfA-A.

7. The engineered lipopeptide synthetase polypeptide of claim 1, wherein the engineered polypeptide comprises a deletion of an A domain and a T domain, relative to the naturally occurring lipopeptide synthetase polypeptide.

8. The engineered polypeptide of claim 7, wherein the engineered polypeptide comprises an A domain and T domain of the second peptide synthetase domain, fused to a C domain which is a hybrid C domain comprising a portion of the C domain of the first peptide synthetase domain and a portion of the C domain of the second peptide synthetase domain.

9. The engineered polypeptide of claim 8, wherein the engineered polypeptide comprises a C domain which comprises a portion of the C domain of the first module of SrfA-A and a portion of the C domain of the second module of SrfA-A, fused to the A domain and T domain of the second module of SrfA-A.

22. A transgenic plant comprising the engineered polypeptide of claim 1.

23. A lipopeptide produced by the engineered polypeptide of claim 1.

10. An engineered lipopeptide synthetase polypeptide comprising:

a first peptide synthetase domain of a first peptide synthetase polypeptide, and

a second peptide synthetase domain of a second peptide synthetase polypeptide,

wherein the first and second peptide synthetase domains are covalently linked such that the engineered lipopeptide synthetase polypeptide produces a lipopeptide comprising an amino acid encoded by the first peptide synthetase domain linked to an amino acid encoded by the second peptide synthetase domain.

11. The engineered polypeptide of claim 10, wherein the first peptide synthetase domain comprises the first module of SrfA-A, and wherein the second peptide synthetase domain comprises a second module of a heterologous synthetase.

12. The engineered polypeptide of claim 10, further comprising a third peptide synthetase domain.

13. An engineered lipopeptide synthetase polypeptide comprising:

a first peptide synthetase domain of a naturally occurring lipopeptide synthetase polypeptide, and

a second peptide synthetase domain of a naturally occurring lipopeptide synthetase polypeptide, wherein the second peptide synthetase domain is covalently linked to a thioesterase domain of a peptide synthetase polypeptide.

14. The engineered polypeptide of claim 13, wherein the first peptide synthetase domain and the second peptide synthetase domain are domains from the same naturally occurring lipopeptide synthetase polypeptide.

15. The engineered polypeptide of claim 13, wherein the first and second domains are from SrfA-A.

16. The engineered polypeptide of claim 13, wherein the first peptide synthetase domain and the thioesterase domain are from the same naturally occurring lipopeptide synthetase polypeptide complex.

17. The engineered polypeptide of claim 16, wherein the first peptide synthetase domain and thioesterase domains are from the SrfA complex.

18-21. -21. (canceled)

24. A lipopeptide consisting of the following amino acid sequence:

L-Glu-D-Leu-L-Val-L-Asp-D-Leu-L-Leu (SEQ ID NO;

______), wherein the lipopeptide comprises a fatty acid moiety on the L-Glu residue.

25. The lipopeptide of claim 24, wherein the lipopeptide is cyclic.

26. A lipopeptide consisting of the following amino acid sequence:

L-Glu-X-D-Leu-L-Val-L-Asp-D-Leu-L-Leu (SEQ ID NO;

______), wherein X is any amino acid, and wherein the lipopeptide comprises a fatty acid moiety on the L-Glu residue.

27. The lipopeptide of claim 26, wherein X is L-Tyr.

28. The lipopeptide of claim 26, wherein the lipopeptide is cyclic.

29. A lipopeptide consisting of the following amino acid sequence:

L-Leu-D-Leu-L-Val-L-Asp-D-Leu-L-Leu (SEQ ID NO;

______), wherein the lipopeptide comprises a fatty acid moiety on the first L-Leu residue.

30. The lipopeptide of claim 29, wherein the lipopeptide is cyclic.

31-34. -34. (canceled)